Slide 1: AROA Biosurgery (ARX) Full Year Results May 2022
AROA BIOSURGERY (ARX) FULL YEAR RESULTS MAY 2022 Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 24 May 2022 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Information in this Presentation The information in this Presentation is of a general bac
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company Product Sales Forecast FY23 Strong FY22 NZ$39m $51-55m1 NZ$56m 81% YoY growth Product Sales cash balance AROA ECM™ platform 6 patented >US$2.5b2 TAM for new products, line extensions product families for existing produ
Slide 4: Products sales have grown 81% YoY
|4 Products sales have grown 81% YoY TotalProduct ProductSales Sales Endoform Sales 12 60 30-40% YoY growth1 8 NZ$m 4 50 0 FY20 FY21 FY22 81% YoY growth Myriad Sales 40 4 NZ$m 3 30 NZ$m 2 1 0 20 FY20 FY21 FY22 TELABio Sales Telabio Sales 10 30 20 NZ$m 10 0 0 FY20 FY21 FY22 FY23 Forecast FY20 FY21 FY
Slide 5: Sales force has grown by 130%
|5 Sales force has grown by 130% Salespeople Salespeople Myriad Active Accounts Active Accounts (Myriad) 1 Endoform Myriad 80 40 70 35 60 30 50 25 40 20 30 15 20 10 5 10 0 0 FY20 FY21 FY22 FY20 FY21 FY22 1. Represents accounts to which sales were made in Q4 of the relevant year.
Slide 6: Manufacturing
|6 Manufacturing Product Gross Gross Margin Margin Manufacturing Manufacturing Facility Facility Capacity 80% 120 100 75% 80 NZ$m 70% 60 40 65% 20 60% 0 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Ongoing margin improvement New facility increases capacity CAPEX (Manufacturing) CAPEX (Manufacturing) 6 5
Slide 7: Use of Funds
|7 Use of Funds Sales Sales & Marketing Expenses & Marketing R&D R&D Spend Investment 20 10 15 NZ$m 5 NZ$m 10 5 0 FY20 FY21 FY22 0 Dead Space Management FY20 FY21 FY22 Existing Product Improvements Cash Cash on OnHand Hand 1 60 50 40 NZ$m 30 20 10 0 FY20 FY21 FY22 FY23 1. As at 31 March of the relev
Slide 8: AROA ECM – Structure & Biology for Regenerative Healing
|8 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach
Slide 9: Substantial Growth Opportunities > $2.5B TAM
|9 Substantial Growth Opportunities > $2.5B1 TAM Complex Wounds Soft Tissue Reconstruction Total Addressable Market Total Addressable Market > $1.4B2 USD > $1.3B3 USD e.g. Diabetic Foot Ulcers, e.g. Trauma, tumour removal, e.g. Hernia repair, abdominal Venous Ulcers, Pressure Ulcers, general surgery
Slide 10: Product portfolio
| 10 Product portfolio Purposefully designed for specific wound types, stage of healing & site of care
Slide 11: Clinical Evidence
| 11 Clinical Evidence Rapid formation of well Tolerated a contaminated No negative inflammatory field and resistant to Reduced surgical vascularized and functional response reported2-5 infection 3-5 complexity4-6 tissue1,2 Myriad Registry Symphony 75 patients Pilot Study - recruited & >2 Completed
Slide 12: Enivo (Dead Space Management Platform)
| 12 Enivo (Dead Space Management Platform) Clinical Need 1. Ousey et. al. (2018) – Surgical wound dehiscence: improving prevention and outcomes 2. Anderson et. al. (2014) – Strategies to prevent surgical site infections in acute care hospitals: 2014 update 3. KCI Prevena Active Incision Management
Slide 13: Outlook
| 13 Outlook TELA Bio® Product Post-COVID AROA Direct Sales Momentum Synergies Improving access, hospital capacity Fully dedicated field sales team. Clinical outcomes & cost Add 10-15 sales representatives Myriad Matrix, Myriad & operating environment, more savings driving increasing in FY23. Morcel
Slide 14: Unlocking regenerative healing for everybody
? Q&A Unlocking regenerative healing for everybody
Slide 15: Contacts
CONTACTS Simon Hinsley Matt Wright Investor Relations Media m +61 401 809 653 m +61 451 896 420 shinsley@aroabio.com matt@nwrcommunications.com.au Visit our website www.aroabio.com and find us on LinkedIn at www.linkedin.com/company/aroa-biosurgery-limited/ 64 Richard Pearse Drive, PO Box 107111, Au